Anticentromere antibody in localized scleroderma

Ruffatti, Amelia; Peserico, Andrea; Glorioso, S; Fiocco, Ugo; Rossi, L; Garnbari, Pierfranca; Todesco, S

doi:10.1016/s0190-9622(86)70217-x

Cited by 47 publications

(18 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antibody has frequently been detected in cases of primary biliary cirrhosis [ 10. 111 and in cases of Raynaud's phenomenon alone [2,7,12]. Additionally, this antibody has been reported to be present occasionally in cases of systemic lupus erythematosus [2,7,13], localized scleroderma [14][15][16] and the blood relatives of patients with systemic scle rosis [5. 17.…”

Section: Discussionmentioning

confidence: 99%

Longitudinal Study of Patients with Anticentromere Antibody

Takehara

Soma²,

Igarashi³

et al. 1990

Dermatology

View full text Add to dashboard Cite

As has previously been reported by many investigators the anticentromere antibody is considered to be a useful serologic marker for the CREST (calcinosis, Raynaud’s phenomenon, esophageal involvement, sclerodactyly and telangiectasia) variant of systemic sclerosis. However, this antibody also appears in other conditions. By screening antinuclear antibody tests using HEp-2 cells as substrate, 39 patients were shown to have the anticentromere antibody. These patients were divided into 4 groups: group 1 = 17 patients with systemic sclerosis; group 2 = 9 patients with Raynaud’s phenomenon alone; group 3 = 7 patients with other connective-tissue diseases, and group 4 = 6 patients with conditions other than those present in groups 1–3. Follow-up over years revealed that some patients suffering solely from Raynaud’s phenomenon (group 2) developed the symptoms of systemic sclerosis. In contrast, of the patients who did not have Raynaud’s phenomenon (group 4), none developed any symptom suggesting systemic sclerosis. We suggest that the simultaneous presence of Raynaud’s phenomenon and the anticentromere antibody predicts the occurrence of systemic sclerosis. In contrast, the presence of the anticentromere antibody alone cannot necessarily be used to predict the development of systemic sclerosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Longitudinal Study of Patients with Anticentromere Antibody

Takehara

Soma²,

Igarashi³

et al. 1990

Dermatology

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that ANA is detected in 4680% of patients with localized scleroderma, as tested with cultured cells, and that the most common pattern of nuclear immunofluorescence is homogeneous (3)(4)(5). However, the antigens that are recognized by the ANA in localized scleroderma remain to be determined.…”

mentioning

confidence: 97%

Antihistone antibodies in patients with localized scleroderma

Sato

Ihn

Soma

et al. 1993

Arthritis & Rheumatism

106

View full text Add to dashboard Cite

Objective. To study the prevalence and antigen specificity of antihistone antibodies (AHA) in localized scleroderma.Methods. Forty-nine serum samples from patients with localized scleroderma were examined by an enzyme-linked immunosorbent assay (ELISA) and by immunoblotting.Results. By ELISA, AHA were demonstrated in 47% (23 of 49) of patients with localized scleroderma and in 87% (13 of 15) of patients with generalized morphea. Immunoblotting revealed that the predominant antigens were histones H1 and H3. The presence of AHA correlated with that of anti-single-stranded DNA antibody.Conclusion. Some of the major antigens for antinuclear antibodies in patients with localized scleroderma are histones.Localized scleroderma is a connective tissue disorder that is limited to the skin and the subcutaneous tissues underlying the cutaneous lesions. This disease differs from systemic sclerosis in that it is not accompanied by Raynaud's phenomenon, acrosclerosis, or involvement of the internal organs, and the From the

show abstract

“…ANA have been detected in 46-80% of patients with localized scleroderma [1][2][3][4][5][6]. Furthermore, we have demonstrated that antihistone antibodies (AHA) are positive in 47% of patients with localized scleroderma and in particular in 87% of patients with generalized morphea, suggesting that the major antigens recognized by ANA are nuclear histones [6,10].…”

Section: Abstract Cd4 · Cd8 · Systemic Sclerosis · Localized Sclerodmentioning

confidence: 99%

“…Immunologic bases are generally considered to be closely involved in the induction of localized scleroderma, since this disorder has been reported to be accompanied by various immunologic abnormalities, such as antinuclear antibodies (ANA), anti-single-stranded DNA (antissDNA) antibody, rheumatoid factor (RF), and lupus erythematosus cell phenomenon [1][2][3][4][5][6][7][8][9]. ANA have been detected in 46-80% of patients with localized scleroderma [1][2][3][4][5][6].…”

Section: Abstract Cd4 · Cd8 · Systemic Sclerosis · Localized Sclerodmentioning

confidence: 99%

Soluble CD4 and CD8 in serum from patients with localized scleroderma

et al. 1996

View full text Add to dashboard Cite

Localized scleroderma has been shown to be accompanied by various immunologic abnormalities. To obtain functional information on activated CD4+ or CD8+ T cells, we studied the levels of soluble CD4 (sCD4) and soluble CD8 (sCD8) in serum from patients with localized scleroderma. Serum samples were examined by enzyme-linked immunosorbent assay. The samples were obtained from 49 patients in the following three subgroups: 15 patients with generalized morphea, 22 with linear scleroderma, and 12 with morphea. The levels of sCD4 and sCD8 were significantly elevated in patients with generalized morphea. Furthermore, these patients showed significantly higher levels of sCD4 than those with systemic sclerosis (SSc). The frequency of positivity for IgG anti-single-stranded DNA (ssDNA) antibody was significantly higher in localized scleroderma patients with elevated sCD4 levels than in patients with normal sCD4 levels. The frequency of positivity for antinuclear antibodies, IgM antihistone antibodies, IgG anti-ssDNA antibody and rheumatoid factor, and elevated sCD23 levels were significantly higher in localized scleroderma patients with elevated sCD8 levels than in patients with normal sCD8 levels. Our findings suggest that both CD4+ and CD8+ T cells are activated in vivo in generalized morphea and that the immunologic events in generalized morphea are different from those in SSc.

show abstract

Anticentromere antibody in localized scleroderma

Cited by 47 publications

References 17 publications

Longitudinal Study of Patients with Anticentromere Antibody

Longitudinal Study of Patients with Anticentromere Antibody

Antihistone antibodies in patients with localized scleroderma

Soluble CD4 and CD8 in serum from patients with localized scleroderma

Contact Info

Product

Resources

About